Mass Spectrometry For Complex Biotherapeutics With KBI's Mass Spec Team

The rising demand for vaccines and complex biotherapeutics has led to an increased role for Contract Development and Manufacturing Organizations (CDMOs) when it comes to supporting the development process. The advanced analytical capabilities offered by CDMOs fulfill a critical step in drug development and manufacturing. Characterizing APIs and managing a diverse population of impurities mitigates safety risks and ensures product quality. Managing process- and product-related impurities in downstream processing is also an essential step to ensure compliance with global regulatory agencies.

Advanced mass spectrometry is powerful tool which can help analyze and characterize complex. It is essential to employ technologies that use fast scanning speeds with high sensitivity and resolution to allow for the most comprehensive analytical options. Effectively characterizing and removing these impurities is critical for developing biotherapeutics and vaccines. Learn more about the analytical services and technological innovations you can gain from partnering with a company like KBI Biopharma.